WEBVTT

1
00:00:00.080 --> 00:00:03.180
Nora's case begins with an
unexpected pregnancy exposure.

2
00:00:03.350 --> 00:00:07.162
Review the product, indication,
dose and timing, and arrange

3
00:00:07.190 --> 00:00:10.170
prompt assessment with the
prescribing and pregnancy-care teams.

4
00:00:10.347 --> 00:00:13.322
Available studies cannot
promise no risk or predict harm

5
00:00:13.334 --> 00:00:14.810
for an individual pregnancy.

6
00:00:14.977 --> 00:00:17.866
Follow the current product guidance
and keep necessary metabolic

7
00:00:17.878 --> 00:00:21.877
care active. Before the
conversation ends, confirm who owns

8
00:00:21.889 --> 00:00:23.967
the next step, how the
patient will reach the

9
00:00:23.979 --> 00:00:25.897
team, and when follow-up will occur.